Clinical Trial Update: A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). [Phase 3]

View source ↗

Summary

Phase 3 open-label, single-arm trial evaluating safety and efficacy of Plerixafor with G-CSF for front-line mobilization in lymphoma and multiple myeloma; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Filgrastim (filgrastim)
• Plerixafor (Plerixafor)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Lymphoma (Non-Hodgkin's Lymphoma), Hodgkin's Disease or Multiple Myeloma | Phase 3 | Status: COMPLETED